Ended December 31, 2018 To The President The Stock Exchange of Thailand Management Discussion and Analysis Consolidated Financial Statements For Financial Year ended December 31, 2018 Overall Group
, Suriyawong, Bangrak, Bangkok 10500, Thailand. Tel. 02-634-0225 Fax 02-634-0135 www.interpharma.co.th Consolidated For the Year Ended December 31 2019 2018 MB % MB % Total revenues 375.89 100.00 317.58 100.00
relation to import duty assessment. งบกาํไรขาดทุนเบ็ดเสร็จ Consolidated For the Year Ended December 31 2019 2018 MB % MB % Total revenues 375.89 100.00 317.58 100.00 Cost of sales (157.39) (41.87) (125.04
relation to import duty assessment. Consolidated For the Year Ended December 31 2019 2018 MB % MB % Total revenues 375.89 100.00 317.58 100.00 Cost of sales (157.39) (41.87) (125.04) (39.77) Selling expenses
December 31, 2019 To The President The Stock Exchange of Thailand Management’s Discussion and Analysis Consolidated Financial Statements For Year Ended December 31, 2019 Overall Group Performance Table 1
Baht according to the consolidated financial statements. The Company could return to having net profit due to be able to transfer the condominium units under the Newera Condominium project as targeted in
Limited (“the Company”) would like to clarify the consolidated financial statements of the Company for the 2nd quarter of fiscal year 2017 ended as of June 30, 2017, which can be summarized as follows
: The President The Stock Exchange of Thailand Aapico Hitech Public Company Limited (“the Company”) would like to clarify the consolidated financial statements of the Company for the fiscal year 2019
, the consolidated financial statements included the business of manufacturing and distribution of dialysis and medical equipment of a subsidiary during Q1 of 2018, with the sales revenue of 84.43 million
March 31, 2019 To The President The Stock Exchange of Thailand Management’s Discussion and Analysis Consolidated Financial Statements For three months ended March 31, 2019 Overall Group Performance Table